Print

HIVIS07

A phase I trial to assess the safety and immunogenicity of a plasmid DNA-MVA prime boost HIV-1 vaccine candidate administered together with dermal electroporation among volunteers in Stockholm, Sweden

Trial Details:

I Completed
Swedish Institute for Infectious Disease Control June 01, 2010
pKCMVgp160A, pKCMVgp160B, pKCMVgp160C, pKCMVp37A(ba), pKCMVp37B2, pKCMVRTmut, pKCMVrev; pKCMVgp160A, pKCMVgp160B, pKCMVgp160C, pKCMVcoPR, pKCMVRTmut, pKCMVp37A(ba), pKCMVp37B2, pKCMVp37C(bc), pKCMVrev, pKCMVnef, pKCMVtat; MVA gag-pol CM 240, env CM235
HIVIS-DNA DNA
MVA-CMDR Viral Vector - Pox
Sweden 48
http://www.controlled-trials.com/ISRCTN60284968